Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly

References

• Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 4 8(Suppl 1):S2-7; PMID:20510263; http://dx.doi.org/10.1016/S1386-6532(10)70002-0
   PubMedGoogle Scholar
• Eshleman E, Shahzad A, Cohrs RJ. Varicella zoster virus latency. Future Virol 2011; 6:341-55; PMID:21695042; http://dx.doi.org/10.2217/fvl.10.90
   PubMed Web of Science ®Google Scholar
• Pickering G, Leplege A. Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Pract 2011; 11:397-402; PMID:21199312; http://dx.doi.org/10.1111/j.1533-2500.2010.00432.x
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1-30; quiz CE2-4
   PubMedGoogle Scholar
• McElhaney JE. Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Rev Vaccines 2009; 8:593-606; PMID:19397416; http://dx.doi.org/10.1586/erv.09.12
   PubMed Web of Science ®Google Scholar
• Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009; 84:274-80; PMID:19252116; http://dx.doi.org/10.4065/84.3.274
   PubMed Web of Science ®Google Scholar
• Toyama N, Shiraki K. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009; 81:2053-8; PMID:19856466; http://dx.doi.org/10.1002/jmv.21599
   PubMed Web of Science ®Google Scholar
• Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology 2013; 81:928-30; PMID:23999562; http://dx.doi.org/10.1212/WNL.0b013e3182a3516e
   PubMed Web of Science ®Google Scholar
• Chapman RS, Cross KW, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine 2003; 21:2541-7; PMID:12744889; http://dx.doi.org/10.1016/S0264-410X(03)00034-3
   PubMed Web of Science ®Google Scholar
• Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, Chosidow O, Blanchon T, Hanslik T. Herpes zoster: Burden of disease in France. Vaccine 2010; 28:7933-8; PMID:20946861; http://dx.doi.org/10.1016/j.vaccine.2010.09.074
   PubMed Web of Science ®Google Scholar
• Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar Herpes Zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013; 13:170; PMID:23574765; http://dx.doi.org/10.1186/1471-2334-13-170
   PubMed Web of Science ®Google Scholar
• Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev Biol (Basel) 2005; 121:153-63; PMID:15962478
   PubMedGoogle Scholar
• Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10:471-86; PMID:21506645; http://dx.doi.org/10.1586/erv.11.29
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087-96; PMID:25916341; http://dx.doi.org/10.1056/NEJMoa1501184
   PubMed Web of Science ®Google Scholar
• Lal H, Zahaf T, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults. Hum Vaccin Immunother 2013; 9:1425-9; PMID:23584252; http://dx.doi.org/10.4161/hv.24269
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapeliere P, Vassilev V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206:1280-90; PMID:22872734; http://dx.doi.org/10.1093/infdis/jis497
   PubMed Web of Science ®Google Scholar
• Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mold JF, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥50 years of age. J Infect Dis 2013; 208:1953-61; PMID:23904292; http://dx.doi.org/10.1093/infdis/jit365
   PubMed Web of Science ®Google Scholar
• Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, Plassmann G, Ledent E, Heineman TC. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 2014; 32:1745-53; PMID:24508036; http://dx.doi.org/10.1016/j.vaccine.2014.01.019
   PubMed Web of Science ®Google Scholar
• Saitoh A, Okabe N. Current issues with the immunization program in Japan: can we fill the “vaccine gap”? Vaccine 2012; 30:4752-6; PMID:22521841; http://dx.doi.org/10.1016/j.vaccine.2012.04.026
   PubMed Web of Science ®Google Scholar
• Zuckerman JN. The importance of injecting vaccines into muscle. Different patients need different needle sizes. BMJ 2000; 321:1237-8; http://dx.doi.org/10.1136/bmj.321.7271.1237
   PubMed Web of Science ®Google Scholar
• Ajana F, Sana C, Caulin E. [Are there differences in immunogenicity and safety of vaccines according to the injection method?]. Med Mal Infect 2008; 38:648-57; PMID:18986787; http://dx.doi.org/10.1016/j.medmal.2008.09.012
   PubMed Web of Science ®Google Scholar
• Cook IF, Barr I, Hartel G, Pond D, Hampson AW. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2006; 24(13):2395-402; PMID:16406171; http://dx.doi.org/10.1016/j.vaccine.2005.11.057
   PubMed Web of Science ®Google Scholar
• de Lalla F, Rinaldi E, Santoro D, Pravettoni G. Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study. Eur J Epidemiol 1988; 4(2):256-8; PMID:2969825; http://dx.doi.org/10.1007/BF00144763
   PubMed Web of Science ®Google Scholar
• Diez-Domingo J, Weinke T, Garcia de Lomas J, Meyer CU, Bertrand I, Eymin C, Thomas S, Sadorge C. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial. Vaccine 2015; 33:789-95; PMID:25555381; http://dx.doi.org/10.1016/j.vaccine.2014.12.024
   PubMed Web of Science ®Google Scholar
• Ruben FL, Froeschle JE, Meschievitz C, Chen K, George J, Reeves-Hoché MK, Pietrobon P, Bybel M, Livingood WC, Woodhouse L. Choosing a route of administration for quadrivalent meningococcal polysaccharide vaccine: intramuscular versus subcutaneous. Clin Infect Dis 2001; 32(1):170-2; PMID:11118395; http://dx.doi.org/10.1086/317553
   PubMed Web of Science ®Google Scholar
• Mark A, Carlsson RM, Granstöm M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 1999; 17(15–16):2067-72; PMID:10217608
   PubMed Web of Science ®Google Scholar
• Rothstein EP, Kamiya H, Nii R, Matsuda T, Bernstein HH, Long SS, Hosbach PH, Meschievitz CK. Comparison of diphtheria-tetanus-two component acellular pertussis vaccines in United States and Japanese infants at 2, 4, and 6 months of age. Pediatrics 1996; 97(2):236-42; PMID:8584384
   PubMed Web of Science ®Google Scholar